Eric Ruderman, MD, discusses the recent FDA approval of vagus nerve stimulation for rheumatoid arthritis. The approval was based on the findings from the RESET-RA trial, which involved multiple locations, including Northwestern Medicine. Dr. Ruderman provides insights on the trial, which evaluated a stimulation device in patients who did not respond to conventional therapies. The trial observed significant improvements in disease activity with active stimulation when compared to patients who didn’t receive stimulation.
Learn more:
source
